| ApoE | Apolipoprotein E |
| COX-2 | Cyclooxygenase-2 |
| CTCAE | Common terminology criteria for adverse events |
| EGF | Epidermal growth factor |
| G-CSF | Granulocyte colony-stimulating factor |
| GIT | Gastrointestinal tract |
| GM-CSF | Granulocyte-macrophage colony stimulating factor |
| IL-1 | Interleukin-1 |
| MAPK | Mitogen-activated protein kinase |
| MMP | Matrix metalloproteinase |
| mTOR | Mammalian target of rapamycin |
| NAC | N-acetyl cysteine |
| NCI | National Cancer Institute |
| NF-κB | Nuclear factor-κB |
| NLRP3 | NACHT, LRR, and PYD domains-containing protein 3 |
| NSAID | Non-steroidal anti-inflammatory drug |
| PARs | Protease-activated receptors |
| PGE | Prostaglandin E |
| PLAG | 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol |
| rhEGF | Recombinant human EGF |
| ROS | Reactive oxygen species |
| SAP | Serum amyloid-P |
| Smad7 | Mothers against decapentaplegic homolog 7 |
| TCM | Traditional Chinese medicine |
| TGF-β | Transforming growth factor-β |
| TNF-α | Tumor necrosis factor-α |